Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 15;12(11):155.
doi: 10.1038/s41408-022-00750-1.

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020

Oliver Van Oekelen  1 , Nicole Birrer  2 , William Wesson  3 , Vincent L Galate  3 , Edward R Scheffer Cliff  4 , Aaron M Goodman  5 , Al-Ola Abdallah  3 , Rajshekhar Chakraborty  6 , Vinay Prasad  7 , Ghulam Rehman Mohyuddin  8
Affiliations
Review

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020

Oliver Van Oekelen et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflict of interest other than the following: AMG reports consulting for Seattle Genetics and EUSA Pharma. VP reports research funding from Arnold Ventures, royalties from Johns Hopkins University Press, consulting fees from United Health Care, and honoraria from EviCore.

Figures

Fig. 1
Fig. 1. Percentage of multiple myeloma clinical trials with measurable residual disease (MRD) and their characteristics over time as reported within ClinicalTrials.gov.
A Percentage of all clinical trials for multiple myeloma (MM) that included MRD assessment split by year of clinical trial start date. B Within MM trials assessing MRD, the percentage of trials that include MRD as a part of the primary endpoint (blue), that include stratification based on MRD (orange) and that are randomized (red) and the change over time. C Within MM trials assessing MRD, distribution of endpoint, trial phase, MRD sensitivity and MRD measurement method and the change over time.
See this image and copyright information in PMC

References

    1. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548–67. - PubMed
    1. Holstein SA, Suman VJ, McCarthy PL. Should overall survival remain an endpoint for multiple myeloma trials? Curr Hematol Malig Rep. 2019;14:31–8. - PMC - PubMed
    1. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e46.. - PubMed
    1. Avet-Loiseau H, Ludwig H, Landgren O, Paiva B, Morris C, Yang H, et al. Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis. Clin Lymphoma Myeloma Leuk. 2020;20:e30–e7. - PMC - PubMed
    1. Cavo M, San-Miguel J, Usmani SZ, Weisel K, Dimopoulos MA, Avet-Loiseau H, et al. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022;139:835–44. - PMC - PubMed